Brookfield Asset Management Inc. Gilead Sciences, Inc. Transaction History

Brookfield Asset Management Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Sep 25, 2023	SELL	$76.01 - $86.7 $2.45 Million - $2.8 Million	-32,291 Reduced 92.45%	2,637 $203,000
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $2.45 Million - $2.8 Million	-32,291 Reduced 92.45%	2,637 $203,000
Q1 2023 Sep 25, 2023	BUY	$77.31 - $88.08 $2.5 Million - $2.84 Million	32,291 Added 1224.54%	34,928 $2.9 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $1.34 Million - $1.53 Million	17,374 Added 98.97%	34,928 $2.9 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $17.6 Million - $25.3 Million	-282,594 Reduced 94.15%	17,554 $1.51 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $6.63 Million - $7.57 Million	111,294 Added 58.93%	300,148 $18.5 Million
Q2 2022 Nov 16, 2022	SELL	$57.72 - $65.01 $6.42 Million - $7.24 Million	-111,294 Reduced 37.08%	188,854 $11.7 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $4.16 Million - $4.68 Million	72,022 Added 61.65%	188,854 $11.7 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $6.77 Million - $8.48 Million	116,832 New	116,832 $6.95 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Brookfield Asset Management Inc. with notifications on news.